<DOC>
	<DOCNO>NCT01799603</DOCNO>
	<brief_summary>The purpose study investigate effect food pharmacokinetics ( explores body drug ) safety TMC435 Japanese healthy adult male participant .</brief_summary>
	<brief_title>A Pharmacokinetic Study Assess Effect Food Healthy Male Participants Receiving TMC435</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single-center , 2-way crossover ( method use switch participant one treatment arm another clinical trial ) randomize ( study drug assign chance ) study assess effect food pharmacokinetics TMC435 single dose Japanese healthy adult male participant . The study duration 44 day per participant , divide 3 part : Screening ( Day -28 Day -2 ) ; Treatment ( consist 2 treatment period 5 day [ , Day -1 4 , in-patient period ] , wherein participant receive TMC435 respective period , period separate washout period 9 day ) ; Follow-up ( Day 7 Period 2 ) . Participants keep upright position time study drug administration 4 hour study drug administration . Participants allow ingest meal 4 hour post-dose . Participants standardize lunch dinner 4 hour 10 hour post-dose , respectively . Drinking water allow 1 hour administration 1 hour administration except water serve study drug meal . Pharmacokinetics assess blood sample collect 72 hour administration study drug . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Be Japanese man age 20 40 year , inclusive day inform consent sign Must agree use adequate contraception method ( example , doublebarrier method ) deem appropriate Investigators study 3 month receive last dose study drug Body mass index ( BMI ) 18.5 25.0 kilogram per square meter ( kg/m^2 ) body weight less 50 kilogram Blood pressure ( participant supine 5 minute ) 90 140 millimeter mercury ( mmHg ) systolic , inclusive , high 90 mmHg diastolic Nonsmoker participant quit tobacco nicotine containing product one year prior screen History current clinically significant medical illness include ( limited ) , cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness Investigator considers exclude participant could interfere interpretation study result Use prescription nonprescription medication ( include vitamin supplement ) within 14 day administration Day 1 treatment Period 1 History drug alcohol abuse within past 5 year positive test drug abuse , cannabinoids , opiate , cocaine , amphetamine , benzodiazepine barbiturate serum alcohol test Known allergy study drug excipients formulation Participated another clinical study receive another study drug administration use experimental medical device within 120 day within period le 10 time drug 's half life , whichever longer , Day 1 first treatment period</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>TMC435</keyword>
	<keyword>G008</keyword>
</DOC>